PITTSBURGH , Oct. 1, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) will report third quarter 2025 financial results on Thursday, November 6, 2025. Company executives will host a webcast at 8:30 a.m.
Viatris continues to struggle with declining sales across all regions, with Q2-2025 net sales down 7% year over year. VTRS's Indore plant issues have significantly impacted results, but a full recovery in 2026 could lead to earnings beats versus consensus estimates. Despite capital returns, persistent sales declines and lack of progress in debt reduction raise concerns about VTRS's long-term in...
PITTSBURGH , Aug. 19, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the appointment of Andrew Enrietti as Chief Administrative and Transformation Officer. In this newly created role, Enrietti will oversee the company's Human Relations, Business Transformation, Information Technology, Information Security, Global Transportation and Security, and G...
Many high-yield S&P 500 stocks are risky, but 19 'safer' dividend dogs have strong free cash flow to support payouts and are worth considering. Analyst forecasts suggest the top ten S&P 500 dividend dogs could deliver 23% to 40% net gains by August 2026, with moderate risk. A market correction or dividend increases could make all top ten 'safer' dividend dogs attractively priced, maximizing yie...
Approval is Another Milestone of Viatris' Ability to Successfully Develop Complex Generic Medicines Approval Granted with Competitive Generic Therapy Eligibility for 100mg/5mL and 200mg/10mL Strengths; Provides Eligibility for 180 Days of Exclusivity PITTSBURGH , Aug. 11, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the U.S. Food and Drug Admini...
Viatris Inc. (NASDAQ:VTRS ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Corinne M. Le Goff - Chief Commercial Officer Philippe Martin - Chief R&D Officer Scott Andrew Smith - CEO & Director Theodora Mistras - Chief Financial Officer William Szablewski - Former Head of Capital Markets Conference Call Participants Ashwani Verma - UBS Investment Bank, Research D...
Drugmaker Viatris beat Wall Street estimates for second-quarter profit and revenue on Thursday, helped by demand for its products in China, sending its shares up nearly 5% in early trading.
Delivers Total Revenues Above Expectations Reflecting the Strength of our Execution and the Resilience of our Diversified Global Business Positive Results From Five Phase 3 Data Readouts This Year Reinforce Continued Momentum of Late-Stage Pipeline Returns More Than $630 Million of Capital to Shareholders Year-to-Date Including $350 Million in Share Buybacks Reiterates 2025 Financial Guidance ...
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.